Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Molecular target therapy in pancreatic and liver cancer

Hani Babiker • 18 Oct 2019
ESMO 2019
Gastrointestinal Cancer Liver Cancer Pancreatic Cancer Atezolizumab Bevacizumab Lenvatinib Olaparib Pembrolizumab

Hani Babiker, MD, The University of Arizona, Tucson, AZ, talks about various updates in the fields of pancreatic and liver cancer, with a focus on molecular-based target therapies. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Hani Babiker

2:54
ILLUMINATE 101: Updates and implications on colorectal cancer
Hani Babiker • 18 Oct 2019
1:20
A promising future for drug development in gastrointestinal cancer
Hani Babiker • 29 Nov 2018
2:43
Current trials in colorectal cancer investigating panitumumab
Hani Babiker • 29 Nov 2018
1:43
Cemiplimab prospects: CRC, CSCC & HNSCC
Hani Babiker • 29 Nov 2018

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:16
Entinostat with nivolumab in pancreatic ductal adenocarcinoma
Marina Baretti • 9 Apr 2024
2:11
COMPASSION-15: cadonilimab in advanced gastric cancers
Yelena Janjigian • 8 Apr 2024
1:28
Evolving biomarker driven therapies to overcome gastric cancer tumor resistance
Yelena Janjigian • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals